GoAI
Get started
Vera Therapeutics, Inc. logo

Vera Therapeutics, Inc.

VERA

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$32.275

+$1.015 · +3.25%

VERA company overview

Historical prices · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

33

Expensive

Momentum

73

Gaining

Sentiment

53

Mixed

Risk resilience

50

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Marshall Fordyce
Listed since
May 14, 2021
Employees
361

Market position

Volume
1.29M
0.76× average
Average volume
1.69M
Average daily volume
Market cap
2.32B USD
Beta
0.95
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.98B USD
P/E (TTM)
-5.51×
P/B (TTM)
5.69×
P/S (TTM)
0×
EV / EBITDA
-10.2×
Earnings yield
-9.21%
Free cash flow yield
-7.43%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-49.56%
Return on assets
-40.78%
Return on invested capital
-46.27%

Financial health

Debt / equity
0.18×
Current ratio
13.64×

Financial statements

Income trends

Operating income

−315.47M USD-88.71%

Net income

−299.62M USD-96.92%
Income trends across reported periods−4.32M USD−117.47M USD−230.61M USD−343.76M USDOperating income, FY2021: −34.4M USDOperating income, FY2022: −90.9M USDOperating income, FY2023: −102.01M USDOperating income, FY2024: −167.17M USDOperating income, FY2025: −315.47M USDNet income, FY2021: −32.61M USDNet income, FY2022: −89.06M USDNet income, FY2023: −95.99M USDNet income, FY2024: −152.15M USDNet income, FY2025: −299.62M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −34.4M USD. Operating income FY2022 −90.9M USD. Operating income FY2023 −102.01M USD. Operating income FY2024 −167.17M USD. Operating income FY2025 −315.47M USD. Net income FY2021 −32.61M USD. Net income FY2022 −89.06M USD. Net income FY2023 −95.99M USD. Net income FY2024 −152.15M USD. Net income FY2025 −299.62M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold———−846K USD—
Gross profit———846K USD—
Research and development215.26M USD126.17M USD78.23M USD69.84M USD22.48M USD
Selling, general, and administrative100.22M USD41M USD23.79M USD21.91M USD11.92M USD
Operating expenses315.47M USD167.17M USD102.01M USD91.75M USD34.4M USD
Interest income24.48M USD20.71M USD7.98M USD1.75M USD15K USD
Interest expense7.53M USD7.63M USD3.79M USD992K USD20K USD
Depreciation and amortization468K USD105K USD21K USD−846K USD176K USD
Operating income−315.47M USD−167.17M USD−102.01M USD−90.9M USD−34.4M USD
Net income−299.62M USD−152.15M USD−95.99M USD−89.06M USD−32.61M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
18%
2 beats, 9 misses, 0 met estimates
Average EPS surprise
-10.77%
11 comparable reports
Latest EPS result
-1.52
Estimate -1.58 · Beat by 3.80%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.64-1.02-1.39-1.77Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual -0.72, estimate -0.83, surprise +13.25%, Beat. Q2 2025, reported May 6, 2025: actual -0.81, estimate -0.75, surprise -8.00%, Miss. Q3 2025, reported Aug 5, 2025: actual -1.2, estimate -0.82, surprise -46.34%, Miss. Q4 2025, reported Nov 5, 2025: actual -1.26, estimate -1.2, surprise -5.00%, Miss. Q1 2026, reported Feb 26, 2026: actual -1.39, estimate -1.34, surprise -3.73%, Miss. Q2 2026, reported May 7, 2026: actual -1.69, estimate -1.33, surprise -27.22%, Miss. Q3 2026, reported Aug 10, 2026: actual -1.52, estimate -1.58, surprise +3.80%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate -1.61, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates4.59M3.18M1.77M362.13KQ2 '26EstimateQ3 '26EstimateQ4 '26Estimate
Q2 2026, reported May 7, 2026: actual —, estimate 426.03K USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 10, 2026: actual —, estimate 1.28M USD, surprise —, Comparison unavailable. Q4 2026, reported Nov 4, 2026: actual —, estimate 4.28M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

14 ratings
Strong buy17%
Buy1286%
Hold17%
Sell00%
Strong sell00%

VERA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding VERA

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
86.73M
Weight
0.76%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
62.38M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
51.24M
Weight
0.06%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
24.42M
Weight
0.03%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
18.56M
Weight
0.12%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
13.62M
Weight
0.13%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
11.51M
Weight
0.06%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
10.15M
Weight
0.04%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%

Continue in GoAI

Research VERA

research.disclaimer